Projects Funded This Year



“The crucial support from Morgan Adams continues to fund all those high-risk, high-reward studies that would otherwise not be possible,” said Rajeev Vibhakar, MD, PhD and Program Leader of Pediatric Neuro-Oncology at the University of Colorado School of Medicine and Children’s Hospital Colorado. “It is these studies that often lead to novel, groundbreaking research projects and subsequent therapeutic interventions.”

2021 Projects Funded

RNASeq “in the round”
Nicholas Foreman

Development of humanized immune system PDX model for evaluating the tumor-immune interaction in pediatric brain tumors
Nicholas Foreman, Andrea Griesinger

Single-nuclei RNA-seq characterization of the tumor microenvironment in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumors
Nicholas Foreman

Targeting BMI1 in ATRT
Rajeev Vibhakar

Targeting H3K27M-mutant DIPG tumors with novel CAR T cell therapy
Sujatha Venkataraman, Rajeev Vibhakar

To investigate the biological effects of radiation and the signaling pathways that promotes radio-resistance of DIPG
Sujatha Venkataraman, Nathan Dahl, Rajeev Vibhakar

Radiation-induced transcriptional adaptation in pediatric high-grade glioma
Nathan Dahl

Understanding the oncogenic role of BMI1 in ependymoma (EPN) PFA tumors at the single-cell transcriptional level
Sujatha Venkataraman, Andrew Donson, Nicholas Foreman, Rajeev Vibhakar

Rational approach to combined targeting of two major transcriptional regulators, EZH2 and CDK9 in MYC-medulloblastoma
Rajeev Vibhakar, Krishna Madhavan

Investigate the molecular pathways regulated by the oncogenic MIC2 in driving H3K27M-DIPG tumorigenesis
Sujatha Venkataraman, Adam Green, Ilango Balakrishnan

Epigenetic Mechanisms of Aurora Kinase Inhibition as a Rational Target in H3K27M-Mutant Diffuse Midline Glioma
Adam Green

Investigation of Components of Potential DIPG and High-Grade Glioma Combination Therapy Trials
Adam Green

Development of CD44 variant 6 targeting chimeric antigen receptor (CAR) T cells in atypical teratoid rhabdoid tumor (ATRT)
Siddhartha Mitra, Anandani Nellan


Development of In Utero driven Mouse Models of Diffused Midline Gliomas to Study the tumor immune interactions in Pediatric Midline Gliomas
Siddhartha Mitra, Santos Franco, Adam Green

Development of Novel Therapies for Atypical Teratoid/Rhabdoid Tumors
Jean M. Mulcahy-Levy

Low-grade glioma immune characterization
Jean M. Mulcahy-Levy, Shadi Zahedi

Advancing Characterization of Epithelial-to-Mesenchymal Transition in ACP through Phospo-kinase Analysis
Todd Hankinson

Preclinical testing of the Immunotherapeutics Nivolumab, Bevacizumab, and Adecatumumab using ex vivo Adamantinomatous Craniopharyngioma Tissue
Todd Hankinson

Intelligent System Design for Interpretable Deep Learning Modeling of Rare Pediatric Brain Tumors from a Multi-disciplinary Perspective
Todd Hankinson

Neurocognitive Function in the Pediatric Hematology-Oncology Population
Claire Fraley

Development of humanized immune system PDX model for evaluating the tumor-immune interaction in pediatric brain tumors
Nicholas Foreman

Targeting Mechanisms of Relapse upon CAR-T Failure in MLLr Leukemia
Patricia Ernst, Terry Fry

Use of ddPCR for Residual Disease Detection (including Post-Transplant) in Pediatric AML 
Amanda Winters

Development of Novel Chimeric Antigen Receptors to Target Antigen-Low Pediatric Leukemia
Mark Eric Kohler

Biomimetic Microenvironments to Model Leptomeningeal Metastasis in Pediatric Neuro-Oncology (Year 3)
Rachael Sirianni

Translating discoveries from brain tumor genomics into new therapeutic strategies 
David A. Solomon

From February 2001 to December 2020, The Morgan Adams Foundation has provided more than $6.1 million in research funds for pilot, seed, and translational studies.

Institutional Partners